TNGX
Tango Therapeutics, Inc.
Healthcare — Biotechnology
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $4.83B |
| P/E Ratio (TTM) | - |
| Forward P/E | -18.77 |
| EPS (TTM) | $-0.83 |
| Dividend Yield | - |
| Profit Margin | -188.15% |
| Revenue Growth | - |
| ROE | -38.42% |
| Debt/Equity | 8.38 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $43.82 |
| Analysts | 11 |
| Next Earnings | Aug 11, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 49.5 |
| Beta | 1.19 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $34.39 |
| 52-Week Low | $5.34 |
| 50-Day Avg | $25.38 |
| 200-Day Avg | $15.28 |
| Avg Volume | $4.17M |
| Volume | 822.0K |
Performance Analysis
NEUTRALTNGX presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report